Irritable Bowel Syndrome (Treatment)

Phase II Trial Data Encouraging for Women

Published in Women's Health Weekly, June 15th, 1998

Results from a Phase II dose ranging trial suggest that the investigational drug alosetron hydrochloride provides adequate relief of pain and discomfort for females with irritable bowel syndrome (IBS).

The results, presented by Allen Mangel, MD, clinical research director, Glaxo Wellcome Inc., during the Digestive Disease Week (DDW) conference in New Orleans, Louisiana, showed that the proportion of female patients who reported adequate relief of IBS-related pain and discomfort was significantly greater with alosetron (1 and 2 mg BID) than the proportion of patients reporting adequate relief with placebo. Female patients taking alosetron also reported improved stool...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1998-06-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry